atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
atezolizumab and hyaluronidase-tqjs is an FDA-licensed reference biologic from Genentech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
Tecentriq Hybreza atezolizumab and hyaluronidase-tqjs
Genentech, Inc.
- Approved
- Sep 12, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for atezolizumab and hyaluronidase-tqjs, in chronological order.
Reference approval
Approval date of the reference atezolizumab and hyaluronidase-tqjs product.
1 yr 9 mo ago
Frequently asked questions
Are there biosimilars approved for atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)?
No 351(k) biosimilars or interchangeable biosimilars referencing atezolizumab and hyaluronidase-tqjs are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.